A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiolo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-05-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849311730109251584 |
|---|---|
| author | Rodrigo Garcia-Salinas Sebastian Magri Alvaro Ruta Santiago Ruta |
| author_facet | Rodrigo Garcia-Salinas Sebastian Magri Alvaro Ruta Santiago Ruta |
| author_sort | Rodrigo Garcia-Salinas |
| collection | DOAJ |
| description |
Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017).
Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other's data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations).
Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre-and-post control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in X-ray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale findings. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls.
Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
|
| format | Article |
| id | doaj-art-b3448c25d3b84a09b05250a47d84d033 |
| institution | Kabale University |
| issn | 0048-7449 2240-2683 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj-art-b3448c25d3b84a09b05250a47d84d0332025-08-20T03:53:18ZengPAGEPress PublicationsReumatismo0048-74492240-26832025-05-0110.4081/reumatismo.2025.1748A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomesRodrigo Garcia-Salinas0https://orcid.org/0000-0002-5928-1092Sebastian Magri1Alvaro Ruta2Santiago Ruta3Rheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La PlataRheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La PlataRheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La PlataRheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La Plata Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017). Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other's data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations). Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre-and-post control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in X-ray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale findings. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls. Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings. https://www.reumatismo.org/reuma/article/view/1748Adalimumabbiosimilarsrheumatoid arthritispsoriatic arthritisultrasonography |
| spellingShingle | Rodrigo Garcia-Salinas Sebastian Magri Alvaro Ruta Santiago Ruta A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes Reumatismo Adalimumab biosimilars rheumatoid arthritis psoriatic arthritis ultrasonography |
| title | A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes |
| title_full | A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes |
| title_fullStr | A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes |
| title_full_unstemmed | A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes |
| title_short | A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes |
| title_sort | comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis a single center experience with a focus on imaging outcomes |
| topic | Adalimumab biosimilars rheumatoid arthritis psoriatic arthritis ultrasonography |
| url | https://www.reumatismo.org/reuma/article/view/1748 |
| work_keys_str_mv | AT rodrigogarciasalinas acomprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT sebastianmagri acomprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT alvaroruta acomprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT santiagoruta acomprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT rodrigogarciasalinas comprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT sebastianmagri comprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT alvaroruta comprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes AT santiagoruta comprehensiveevaluationofthetransitiontoabiosimilarofadalimumabinrheumatoidarthritisandpsoriaticarthritisasinglecenterexperiencewithafocusonimagingoutcomes |